Would you consider transitioning patients older than 75 years of age with coronary disease from statins and/or other lipid-lowering agents to PCSK9 inhibitors given concerns for polypharmacy, provided their LDL levels remain at or below goal?

How has your treatment strategy evolved with the recent changes in ACC/AHA clinical guidelines and the FDA label allowing for PCSK9 inhibitor use without concurrent statin therapy?

• I have expanded the use of PCSK9 inhibitors as an alternative for patients with contraindications to statins
• I routinely add PCSK9 inhibitors for patients not reaching LDL goals with statins alone
• I have started prescribing PCSK9 inhibitors as a first-line therapy for certain patients
• I have not changed my treatment strategy significantly, continuing primarily with statins and adding PCSK9 inhibitors selectively
• I plan to increase my adoption of PCSK9 inhibitors for my patients in the future
• Other